Solriamfetol improves daytime sleepiness irrespective of sleep apnea treatment: Study
USA: Solriamfetol improves excessive daytime sleepiness (EDS) in obstructive sleep apnea (OSA) regardless of primary OSA therapy adherence, finds a recent study in the journal Chest.
Solriamfetol is a dopamine-norepinephrine reuptake inhibitor that is approved in the USA for improving wakefulness in people with EDS associated with OSA. Paula K. Schweitzer, St. Luke's Hospital, Chesterfield, MO, USA, and colleagues aimed to determine whether solriamfetol have differential effects on EDS based on adherence to primary OSA therapy and does solriamfetol affect primary OSA therapy usage.
Participants were randomized to 12 weeks of placebo or solriamfetol 37.5, 75, 150, or 300 mg/d (stratified by primary OSA therapy adherence).
Coprimary endpoints were week-12 change from baseline in Maintenance of Wakefulness Test (40-minute MWT) and Epworth Sleepiness Scale (ESS) in the modified intent-to-treat population. The researchers evaluated primary OSA therapy use (hours/night, % nights) and safety.
Key findings of the study include:
- At baseline, 324 (70.6%) participants were adherent (positive airway pressure use ≥4 hours/night on ≥70% nights, surgical intervention, or oral appliance use on ≥70% nights) and 135 (29.4%) nonadherent.
- Least squares (LS) mean differences (95% CI) from placebo in MWT sleep latency (minutes) in the 37.5-, 75-, 150-, and 300-mg groups among adherent participants were 4.8, 8.4, 10.2, 12.5 and among nonadherent participants were 3.7, 9.9, 11.9, 13.5.
- On ESS, LS mean differences from placebo in the 37.5-, 75-, 150-, and 300-mg groups among adherent participants were -2.4, -1.3, -4.2, -4.7 and among nonadherent participants were -0.7, -2.6, -5.0, -4.6 (-7.0, -2.3).
- Common adverse events: headache, nausea, anxiety, decreased appetite, nasopharyngitis, diarrhea.
- No clinically meaningful changes were seen in primary OSA therapy use with solriamfetol.
"Solriamfetol improved EDS in OSA regardless of primary OSA therapy adherence. Primary OSA therapy use was unaffected with solriamfetol," wrote the authors.
The study titled, "Randomized Controlled Trial of Solriamfetol for Excessive Daytime Sleepiness in Obstructive Sleep Apnea: An Analysis of Subgroups Adherent or Nonadherent to Obstructive Sleep Apnea Treatment," is published in the journal CHEST.
DOI: https://journal.chestnet.org/article/S0012-3692(21)00341-X/
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.